For neuropathic pain, optimize opioids.
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D058647:Adrenergic alpha-2 Receptor Agonists; D000700:Analgesics / Q000627:therapeutic use; D000927:Anticonvulsants / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000627:therapeutic use; D002908:Chronic Disease; D006801:Humans; D009294:Narcotics / Q000627:therapeutic use*; D009369:Neoplasms / Q000150:complications* / Q000188:drug therapy; D009437:Neuralgia / Q000188:drug therapy* / Q000209:etiology*; D018341:Receptors, Adrenergic, alpha-2 / Q000627:therapeutic use; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D026941:Sodium Channel Blockers / Q000627:therapeutic use
D000305:Adrenal Cortex Hormones; D058647:Adrenergic alpha-2 Receptor Agonists; D000700:Analgesics; D000927:Anticonvulsants; D000928:Antidepressive Agents; D009294:Narcotics; D018341:Receptors, Adrenergic, alpha-2; D016194:Receptors, N-Methyl-D-Aspartate; D026941:Sodium Channel Blockers